Acridine: A Scaffold for the Development of Drugs for Alzheimer's Disease
Authors:
- 1 May 2023
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 23 (13) , 1260-1276
Abstract
Alzheimer's disease (AD) is drawing scientists' consideration, being one of the gravest diseases mankind will have to battle against in the near future. The number of people with AD is expected to triple in the next 40 years. It is a most common age-related multifactorial neurodegen-erative disease and characterized by two histopathological hallmarks; the formation of senile plaques composed of the amyloid-β (Aβ) peptide and neurofibrillary tangles composed of hyper-phosphorylated tau protein. Discovery and development of rationally designed multi-targeted lig-ands for the management of AD could be more beneficial than classical single targeted molecules. Acridine, a heterocyclic nucleus is a sole moiety in various existing drug molecules such as quina-crine (antimalarial), acriflavine and proflavine (antiseptics), ethacridine (abortifacient), amsacrine and nitracine (anticancer) and tacrine (anti-Alzheimer). It is proposed that acridine may combat the AD by acting on several targets like acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), dual specificity tyrosine kinase 1A (Dyrk 1A), amyloid and prion protein (PrPC) etc. involved in its pathogenesis. The main aim of this compilation is to review the most promising therapeutic devel-opments within the vast research area dealing with acridine derivatives. Further research is required to evaluate the effectiveness of the acridine derivatives with various substitutions in the treatment of AD. In conclusion, our review will suggest the potentiality of the versatile acridine framework for drug designing and developing novel multi-target inhibitors for the Alzheimer’s disease.Keywords
This publication has 108 references indexed in Scilit:
- Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate RecognitionStructure, 2013
- Structure-activity relationship of acridine derivatives to amyloid aggregation of lysozymeBiochimica et Biophysica Acta (BBA) - General Subjects, 2011
- PrionsCold Spring Harbor Perspectives in Biology, 2011
- The role of DYRK1A in neurodegenerative diseasesThe FEBS Journal, 2010
- Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- Synthesis of biologically active N-methyl derivatives of amidines and cyclized five-membered products of amidines with oxalyl chlorideEuropean Journal of Medicinal Chemistry, 2008
- Structural insights into substrate traffic and inhibition in acetylcholinesteraseThe EMBO Journal, 2006
- DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and NeurogenesisThe Scientific World Journal, 2006
- Biochemistry and structure of PrPC and PrPScBritish Medical Bulletin, 2003
- Neurobiology of butyrylcholinesteraseNature Reviews Neuroscience, 2003